BridgeBio Pharma, Inc. Stockholders' Equity Attributable to Noncontrolling Interest
BridgeBio Pharma, Inc. (BBIO) had Stockholders' Equity Attributable to Noncontrolling Interest of $10.34 million as of 2026-06-30, per its 10-Q filed 2026-08-10.
Financial Statements › Balance Sheet › Equity › Equity, Including Portion Attributable to Noncontrolling Interest
us-gaap:MinorityInterest · last filed 2026-08-10
- 2026-06-30: Stockholders' Equity Attributable to Noncontrolling Interest $10.34M.
- 2026-03-31: Stockholders' Equity Attributable to Noncontrolling Interest $10.44M.
- 2025-12-31: Stockholders' Equity Attributable to Noncontrolling Interest $10.60M.
- 2025-09-30: Stockholders' Equity Attributable to Noncontrolling Interest $10.32M.
| Period end | Stockholders' Equity Attributable to Noncontrolling Interest |
|---|---|
| 2026-06-30 | $10.34M 10-Q · filed 2026-08-10 |
| 2026-03-31 | $10.44M 10-Q · filed 2026-05-07 |
| 2025-12-31 | $10.60M 10-Q · filed 2026-08-10 |
| 2025-09-30 | $10.32M 10-Q · filed 2025-10-29 |
| 2025-06-30 | $9.89M 10-Q · filed 2025-08-05 |
| 2025-03-31 | $9.96M 10-Q · filed 2025-04-29 |
| 2024-12-31 | $10.15M 10-K · filed 2026-02-24 |
| 2024-09-30 | $10.88M 10-Q · filed 2024-11-12 |
| 2024-06-30 | $11.05M 10-Q · filed 2024-08-01 |
| 2024-03-31 | $12.14M 10-Q · filed 2024-05-02 |
| 2023-12-31 | $11.24M 10-K · filed 2025-02-20 |
| 2023-09-30 | $12.40M 10-Q · filed 2023-11-02 |
| 2023-06-30 | $12.05M 10-Q · filed 2023-08-03 |
| 2023-03-31 | $12.26M 10-Q · filed 2023-05-04 |
| 2022-12-31 | $11.28M 10-K · filed 2024-02-22 |
| 2022-09-30 | $10.43M 10-Q · filed 2022-11-03 |
| 2022-06-30 | $12.02M 10-Q · filed 2022-08-04 |
| 2022-03-31 | -$27.00K 10-Q · filed 2022-05-05 |
| 2021-12-31 | $3.41M 10-K · filed 2023-02-23 |
| 2021-09-30 | $4.56M 10-Q · filed 2021-11-04 |
| 2021-06-30 | $6.80M 10-Q · filed 2021-08-05 |
| 2021-03-31 | $5.93M 10-Q · filed 2021-05-06 |
| 2020-12-31 | $48.35M 10-K · filed 2022-02-25 |
| 2020-09-30 | $52.06M 10-Q · filed 2020-11-05 |
| 2020-06-30 | $59.85M 10-Q · filed 2020-11-05 |
| 2020-03-31 | $68.30M 10-Q · filed 2020-11-05 |
| 2019-12-31 | $65.28M 10-K · filed 2021-02-25 |
| 2019-09-30 | $61.94M 10-Q · filed 2019-11-08 |
| 2019-06-30 | $48.39M 10-Q · filed 2020-08-11 |
| 2019-03-31 | $58.32M 10-Q · filed 2020-05-14 |
| 2018-12-31 | $62.36M 10-K · filed 2020-03-03 |
| 2017-12-31 | $2.50M 10-K · filed 2020-03-03 |
| 2016-12-31 | $2.60M 10-K · filed 2020-03-03 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |
| BIOMARIN PHARMACEUTICAL INC (BMRN) | United States | $11.879B | 151.80 |
| MADRIGAL PHARMACEUTICALS, INC. (MDGL) | United States | $11.859B | -38.17 |
| Elanco Animal Health Inc (ELAN) | United States | $11.177B | -61.80 |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 | |
| Axsome Therapeutics, Inc. (AXSM) | United States | $10.274B | -66.82 |
| ARROWHEAD PHARMACEUTICALS, INC. (ARWR) | United States | $9.331B | -42.28 |
| CYTOKINETICS INC (CYTK) | United States | $9.130B | -11.86 |
| Protagonist Therapeutics, Inc (PTGX) | United States | $8.883B | 95.52 |